Skip to Main Content

Paper Details

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Breast Cancer Res Treat
22
2021
CACNA1S, CD8, CFAP58, COL22A1, COL4A5, CTLA4, EGFR, IDO1, KPRP, L1CAM, PCDHA1, PD-L1, PD-L2, Patients, RAD51AP2, RB1, SDK2, TNBC, TP53, Tregs, cancer, carboplatin, cytotoxic cells, docetaxel, exhausted CD8, immune gene signatures, interferon gamma, pCR, patients, pre, triple-negative breast cancer, tumor, tumor inflammation, tumors
Author NameAffiliation
Foluso O AdemuyiwaWashington University School of Medicine
Mothaffar F RimawiLester & Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Ian S HagemannWashington University School of Medicine
Zachary L SkidmoreMcDonnell Genome Institute, Washington University School of Medicine
Megan M RichtersMcDonnell Genome Institute, Washington University School of Medicine
Cynthia X MaWashington University School of Medicine
Ron BoseWashington University School of Medicine
Meenakshi AnuragLester & Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Matthew J EllisLester & Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine
  • 1 - 11

Datasets

Release 1.2